Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANNE MAITLAND

Allopathic & Osteopathic Physicians Allergy & Immunology Allergy

NPI
1083660047
CMS profile
49288
Location
TARRYTOWN, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$95,746.58

151 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $72,587.00 28
Travel and Lodging $19,578.41 71
Food and Beverage $3,188.55 49
Consulting Fee $353.00 1
Education $39.62 2

By paying entity

PY2023 · entire year · sorted by reported total

Page 4 of 4; records 151–151 of 151 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANNE MAITLAND

NPI 1083660047 · CMS profile ID 49288

Allopathic & Osteopathic Physicians / Allergy & Immunology / Allergy

TARRYTOWN, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–151 of 151 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1083660047?year=2023&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANNE MAITLAND, NPI 1083660047, CMS profile ID 49288. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–151 of 151 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083660047?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ANNE MAITLAND, NPI 1083660047, CMS profile ID 49288. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–151 of 151 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083660047?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ANNE MAITLAND, NPI 1083660047, CMS profile ID 49288, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–151 of 151 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1083660047?year=2023&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

151 matching records · $95,746.58 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 151 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–151 of 151.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $19.8502/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003236441 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $57,124.56 116
PY2020 $17,358.14 29
PY2021 $1,484.84 8
PY2022 $11,011.13 28
PY2023 $95,746.58 151
PY2024 $89,439.38 124
PY2025 $19,786.82 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $327,422.15 168
PY2023 Principal investigator $6,393.54 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

168 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ARGENX US, INC. $28,539.80 09/11/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142161148
Principal investigator 1 ARGENX US, INC. $1,445.00 08/16/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161160
Principal investigator 1 ARGENX US, INC. $433.50 08/16/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161172
Principal investigator 1 ARGENX US, INC. $1,445.00 08/16/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161174
Principal investigator 1 ARGENX US, INC. $1,445.00 08/16/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161176
Principal investigator 1 ARGENX US, INC. $1,445.00 08/16/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161178
Principal investigator 1 ARGENX US, INC. $1,445.00 08/16/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161180
Principal investigator 1 ARGENX US, INC. $1,445.00 08/16/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161182
Principal investigator 1 ARGENX US, INC. $2,423.00 07/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161150
Principal investigator 1 ARGENX US, INC. $2,423.00 07/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161152
Principal investigator 1 ARGENX US, INC. $2,946.00 07/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161154
Principal investigator 1 ARGENX US, INC. $2,423.00 07/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161156
Principal investigator 1 ARGENX US, INC. $2,423.00 07/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161158
Principal investigator 1 ARGENX US, INC. $1,021.00 07/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161162
Principal investigator 1 ARGENX US, INC. $1,021.00 07/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161164
Principal investigator 1 ARGENX US, INC. $1,021.00 07/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161166
Principal investigator 1 ARGENX US, INC. $1,021.00 07/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161168
Principal investigator 1 ARGENX US, INC. $942.80 07/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161170
Principal investigator 1 ARGENX US, INC. $2,423.00 07/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161184
Principal investigator 1 ARGENX US, INC. $2,423.00 07/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161186
Principal investigator 1 ARGENX US, INC. $1,098.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160940
Principal investigator 1 ARGENX US, INC. $1,021.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160950
Principal investigator 1 ARGENX US, INC. $1,021.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160962
Principal investigator 1 ARGENX US, INC. $1,652.20 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160964
Principal investigator 1 ARGENX US, INC. $1,021.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160968
Principal investigator 1 ARGENX US, INC. $1,021.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160972
Principal investigator 1 ARGENX US, INC. $1,021.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160986
Principal investigator 1 ARGENX US, INC. $1,210.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160990
Principal investigator 1 ARGENX US, INC. $1,210.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160992
Principal investigator 1 ARGENX US, INC. $1,021.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160996
Principal investigator 1 ARGENX US, INC. $1,210.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161000
Principal investigator 1 ARGENX US, INC. $1,021.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161004
Principal investigator 1 ARGENX US, INC. $1,210.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161006
Principal investigator 1 ARGENX US, INC. $1,021.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161010
Principal investigator 1 ARGENX US, INC. $1,021.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161012
Principal investigator 1 ARGENX US, INC. $1,098.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161064
Principal investigator 1 ARGENX US, INC. $1,098.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161066
Principal investigator 1 ARGENX US, INC. $1,098.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161068
Principal investigator 1 ARGENX US, INC. $1,098.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161070
Principal investigator 1 ARGENX US, INC. $1,098.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161072
Principal investigator 1 ARGENX US, INC. $1,098.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161074
Principal investigator 1 ARGENX US, INC. $1,098.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161076
Principal investigator 1 ARGENX US, INC. $1,098.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161078
Principal investigator 1 ARGENX US, INC. $1,098.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161080
Principal investigator 1 ARGENX US, INC. $1,098.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161082
Principal investigator 1 ARGENX US, INC. $1,210.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161092
Principal investigator 1 ARGENX US, INC. $1,021.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161116
Principal investigator 1 ARGENX US, INC. $1,021.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161118
Principal investigator 1 ARGENX US, INC. $1,021.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161120
Principal investigator 1 ARGENX US, INC. $1,021.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161122
Principal investigator 1 ARGENX US, INC. $1,021.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161124
Principal investigator 1 ARGENX US, INC. $1,021.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161126
Principal investigator 1 ARGENX US, INC. $1,021.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161128
Principal investigator 1 ARGENX US, INC. $1,021.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161130
Principal investigator 1 ARGENX US, INC. $1,021.00 06/14/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161132
Principal investigator 1 ARGENX US, INC. $750.00 05/17/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160952
Principal investigator 1 ARGENX US, INC. $515.00 05/17/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160956
Principal investigator 1 ARGENX US, INC. $20,349.00 05/17/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160958
Principal investigator 1 ARGENX US, INC. $750.00 05/17/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160982
Principal investigator 1 ARGENX US, INC. $82.00 05/17/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161036
Principal investigator 1 ARGENX US, INC. $82.00 05/17/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161038
Principal investigator 1 ARGENX US, INC. $5,814.00 05/17/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161048
Principal investigator 1 ARGENX US, INC. $1,210.00 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160934
Principal investigator 1 ARGENX US, INC. $1,021.00 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160938
Principal investigator 1 ARGENX US, INC. $1,183.00 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160942
Principal investigator 1 ARGENX US, INC. $1,664.50 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160944
Principal investigator 1 ARGENX US, INC. $1,382.00 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160974
Principal investigator 1 ARGENX US, INC. $1,021.00 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160978
Principal investigator 1 ARGENX US, INC. $1,021.00 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160980
Principal investigator 1 ARGENX US, INC. $1,021.00 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160988
Principal investigator 1 ARGENX US, INC. $1,382.00 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160998
Principal investigator 1 ARGENX US, INC. $1,021.00 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161020
Principal investigator 1 ARGENX US, INC. $1,021.00 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161026
Principal investigator 1 ARGENX US, INC. $645.00 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161050
Principal investigator 1 ARGENX US, INC. $1,098.00 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161052
Principal investigator 1 ARGENX US, INC. $1,098.00 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161054
Principal investigator 1 ARGENX US, INC. $1,882.00 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161056
Principal investigator 1 ARGENX US, INC. $1,882.00 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161058
Principal investigator 1 ARGENX US, INC. $1,882.00 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161060
Principal investigator 1 ARGENX US, INC. $1,382.00 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161088
Principal investigator 1 ARGENX US, INC. $1,382.00 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161090
Principal investigator 1 ARGENX US, INC. $1,210.00 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161112
Principal investigator 1 ARGENX US, INC. $1,021.00 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161136
Principal investigator 1 ARGENX US, INC. $1,021.00 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161138
Principal investigator 1 ARGENX US, INC. $1,021.00 05/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161140
Principal investigator 1 ARGENX US, INC. $1,500.00 05/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160874
Principal investigator 1 ARGENX US, INC. $114.00 05/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160892
Principal investigator 1 ARGENX US, INC. $905.00 05/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142161094
Principal investigator 1 ARGENX US, INC. $1,500.00 05/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142161142
Principal investigator 1 ARGENX US, INC. $2,035.40 05/01/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160868
Principal investigator 1 ARGENX US, INC. $953.00 05/01/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160870
Principal investigator 1 ARGENX US, INC. $3,180.00 05/01/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160886
Principal investigator 1 ARGENX US, INC. $3,180.00 05/01/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160888
Principal investigator 1 ARGENX US, INC. $953.00 05/01/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142161062
Principal investigator 1 ARGENX US, INC. $76.00 04/12/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160872
Principal investigator 1 ARGENX US, INC. $2,715.00 04/12/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160898
Principal investigator 1 ARGENX US, INC. $1,183.00 04/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160926
Principal investigator 1 ARGENX US, INC. $1,382.00 04/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160928
Principal investigator 1 ARGENX US, INC. $1,882.00 04/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160930
Principal investigator 1 ARGENX US, INC. $1,098.00 04/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160932
Principal investigator 1 ARGENX US, INC. $645.00 04/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161014
Principal investigator 1 ARGENX US, INC. $1,183.00 04/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161016
Principal investigator 1 ARGENX US, INC. $645.00 04/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161018
Principal investigator 1 ARGENX US, INC. $1,183.00 04/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161022
Principal investigator 1 ARGENX US, INC. $645.00 04/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161024
Principal investigator 1 ARGENX US, INC. $1,382.00 04/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161028
Principal investigator 1 ARGENX US, INC. $1,882.00 04/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161030
Principal investigator 1 ARGENX US, INC. $1,183.00 04/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161032
Principal investigator 1 ARGENX US, INC. $1,183.00 04/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161034
Principal investigator 1 ARGENX US, INC. $1,615.20 04/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161040
Principal investigator 1 ARGENX US, INC. $1,021.00 04/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161096
Principal investigator 1 ARGENX US, INC. $1,021.00 04/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161098
Principal investigator 1 ARGENX US, INC. $1,021.00 04/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161100
Principal investigator 1 ARGENX US, INC. $1,021.00 04/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161102
Principal investigator 1 ARGENX US, INC. $1,021.00 04/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161104
Principal investigator 1 ARGENX US, INC. $1,382.00 04/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161108
Principal investigator 1 ARGENX US, INC. $645.00 04/10/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161134
Principal investigator 1 ARGENX US, INC. $3,180.00 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160876
Principal investigator 1 ARGENX US, INC. $953.00 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160878
Principal investigator 1 ARGENX US, INC. $953.00 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160880
Principal investigator 1 ARGENX US, INC. $953.00 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160882
Principal investigator 1 ARGENX US, INC. $3,180.00 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160884
Principal investigator 1 ARGENX US, INC. $953.00 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160894
Principal investigator 1 ARGENX US, INC. $953.00 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160896
Principal investigator 1 ARGENX US, INC. $3,180.00 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160900
Principal investigator 1 ARGENX US, INC. $953.00 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160902
Principal investigator 1 ARGENX US, INC. $953.00 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160936
Principal investigator 1 ARGENX US, INC. $953.00 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160946
Principal investigator 1 ARGENX US, INC. $953.00 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160948
Principal investigator 1 ARGENX US, INC. $953.00 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160954
Principal investigator 1 ARGENX US, INC. $953.00 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160960
Principal investigator 1 ARGENX US, INC. $953.00 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160966
Principal investigator 1 ARGENX US, INC. $953.00 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160970
Principal investigator 1 ARGENX US, INC. $953.00 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160976
Principal investigator 1 ARGENX US, INC. $953.00 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160984
Principal investigator 1 ARGENX US, INC. $953.00 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160994
Principal investigator 1 ARGENX US, INC. $953.00 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142161002
Principal investigator 1 ARGENX US, INC. $953.00 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142161008
Principal investigator 1 ARGENX US, INC. $59.30 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142161042
Principal investigator 1 ARGENX US, INC. $1,333.00 04/03/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142161114
Principal investigator 1 ARGENX US, INC. $864.00 03/15/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160860
Principal investigator 1 ARGENX US, INC. $5,430.00 03/15/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160862
Principal investigator 1 ARGENX US, INC. $71,495.00 03/15/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160864
Principal investigator 1 ARGENX US, INC. $646.00 03/15/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160866
Principal investigator 1 ARGENX US, INC. $38.00 03/15/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) No dispute reported 06/30/2026 1142160890
Principal investigator 1 ARGENX US, INC. $349.00 03/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160910
Principal investigator 1 ARGENX US, INC. $1,107.00 03/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160912
Principal investigator 1 ARGENX US, INC. $1,098.00 03/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160914
Principal investigator 1 ARGENX US, INC. $645.00 03/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160916
Principal investigator 1 ARGENX US, INC. $1,021.00 03/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160922
Principal investigator 1 ARGENX US, INC. $1,183.00 03/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161084
Principal investigator 1 ARGENX US, INC. $645.00 03/13/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161086
Principal investigator 1 ARGENX US, INC. $82.00 03/08/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161046
Principal investigator 1 ARGENX US, INC. $4,845.00 03/08/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161110
Principal investigator 1 ARGENX US, INC. $2,500.00 03/01/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160904
Principal investigator 1 ARGENX US, INC. $78.90 03/01/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161188
Principal investigator 1 ARGENX US, INC. $92.05 03/01/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161190
Principal investigator 1 ARGENX US, INC. $222.60 03/01/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161192
Principal investigator 1 ARGENX US, INC. $222.60 03/01/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161194
Principal investigator 1 ARGENX US, INC. $1,021.00 02/09/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160918
Principal investigator 1 ARGENX US, INC. $2,946.00 02/09/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160920
Principal investigator 1 ARGENX US, INC. $387.30 02/09/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161044
Principal investigator 1 ARGENX US, INC. $1,021.00 02/09/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161144
Principal investigator 1 ARGENX US, INC. $1,021.00 02/09/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161146
Principal investigator 1 ARGENX US, INC. $1,210.00 01/17/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160906
Principal investigator 1 ARGENX US, INC. $586.00 01/17/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160908
Principal investigator 1 ARGENX US, INC. $1,021.00 01/17/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142160924
Principal investigator 1 ARGENX US, INC. $1,098.00 01/17/2024 Non-covered Recipient Entity
Metrodora Institute
Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 No dispute reported 06/30/2026 1142161106